Adgero Biopharmaceuticals

Adgero Biopharmaceuticals is a biopharmaceutical company engaged in developing photodynamic therapy to address rare and unmet medical needs in oncology. The company's lead product, REM-001 Therapy, combines a laser light source, a light delivery device, and a therapeutic drug, and is currently undergoing Phase 2/3 clinical trials for conditions such as cutaneous metastatic cancers and basal cell nevus syndrome. This therapy has shown promising safety and efficacy in prior studies, particularly for patients with cutaneous metastatic breast cancer who have not responded to radiation therapy. Adgero Biopharmaceuticals aims to build its pipeline by advancing this proprietary therapy platform, which utilizes photosensitizers to induce local tumor cell death upon light exposure. Founded in 2007 and based in Pittstown, New Jersey, the company was previously known as Adgero Biopharmaceuticals, Inc. before rebranding in 2016.